NO20010284D0 - Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP) - Google Patents

Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP)

Info

Publication number
NO20010284D0
NO20010284D0 NO20010284A NO20010284A NO20010284D0 NO 20010284 D0 NO20010284 D0 NO 20010284D0 NO 20010284 A NO20010284 A NO 20010284A NO 20010284 A NO20010284 A NO 20010284A NO 20010284 D0 NO20010284 D0 NO 20010284D0
Authority
NO
Norway
Prior art keywords
pacap
adenylate cyclase
peptide analogs
activating polypeptide
pituitary adenylate
Prior art date
Application number
NO20010284A
Other languages
English (en)
Other versions
NO20010284L (no
Inventor
Zheng Xin Dong
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20010284D0 publication Critical patent/NO20010284D0/no
Publication of NO20010284L publication Critical patent/NO20010284L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
NO20010284A 1998-07-20 2001-01-17 Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP) NO20010284L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11954098A 1998-07-20 1998-07-20
PCT/EP1999/003020 WO2000005260A1 (en) 1998-07-20 1999-04-30 Peptide analogues of pacap

Publications (2)

Publication Number Publication Date
NO20010284D0 true NO20010284D0 (no) 2001-01-17
NO20010284L NO20010284L (no) 2001-03-19

Family

ID=22384966

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010284A NO20010284L (no) 1998-07-20 2001-01-17 Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP)

Country Status (15)

Country Link
EP (2) EP1098906B1 (no)
JP (2) JP2002521390A (no)
AR (1) AR019131A1 (no)
AT (1) ATE449789T1 (no)
AU (1) AU3826899A (no)
CA (1) CA2335341A1 (no)
CZ (1) CZ2001253A3 (no)
DE (1) DE69941708D1 (no)
DK (1) DK1098906T3 (no)
ES (1) ES2335827T3 (no)
HU (1) HUP0104934A3 (no)
NO (1) NO20010284L (no)
PL (1) PL345583A1 (no)
TW (1) TWI221845B (no)
WO (1) WO2000005260A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972319B1 (en) 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
SK5552002A3 (en) * 1999-09-28 2003-05-02 Bayer Ag Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
JP2004500906A (ja) 1999-11-12 2004-01-15 ルーベン，　レオ 電気的調節および化学的調節のための心臓デバイス、ならびに心肺障害の処置のための血管作用性腸ペプチド
WO2001060862A1 (en) * 2000-02-18 2001-08-23 Dabur Research Foundation Vasoactive intestinal peptide analogs
ATE355304T1 (de) * 2000-02-18 2006-03-15 Dabur Res Foundation Radiomarkierte vip-analoge zur diagnose und therapie
CN101229363A (zh) 2000-11-28 2008-07-30 蒙多生物技术许可股份公司 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物
JP2002293799A (ja) * 2001-03-29 2002-10-09 Itoham Foods Inc 新規ペプチド及びそれを含有する消化管運動抑制剤
US7048934B2 (en) 2001-08-30 2006-05-23 Stem Cell Therapeutics Inc. Combined regulation of neural cell production
JP4906231B2 (ja) * 2001-09-14 2012-03-28 ステム セル セラピューティクス インコーポレイテッド プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途
CA2485216A1 (en) * 2002-05-03 2003-11-13 Neuronova Ab Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
US20060241028A1 (en) * 2002-06-10 2006-10-26 Dorian Bevec Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
CA2492442A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
US7615219B2 (en) 2003-01-16 2009-11-10 Life Sciences Research Partners Vzw Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia
US7846898B2 (en) 2004-02-13 2010-12-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
US7595294B2 (en) * 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
JP2006306770A (ja) * 2005-04-27 2006-11-09 Nidek Co Ltd 眼疾患治療剤
KR20080074108A (ko) 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
US7582608B2 (en) 2005-10-26 2009-09-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
EP2496245B1 (en) * 2009-11-02 2016-07-20 The Administrators Of The Tulane Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CA2901231C (en) * 2013-02-15 2020-06-23 Thomas Jefferson University Kit comprising lyophilized compositions for tumor imaging
EA032830B1 (ru) 2013-03-15 2019-07-31 Эмджен Инк. Антитела к pac1 человека и их применение для лечения головной боли
WO2014197909A1 (en) * 2013-06-07 2014-12-11 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
WO2015023890A1 (en) * 2013-08-14 2015-02-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
US9989541B2 (en) 2013-12-27 2018-06-05 Dignity Health Diagnosing and treating alzheimer's disease
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
WO2018129200A2 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
BR112020013621A2 (pt) 2018-01-12 2020-12-01 Amgen Inc. anticorpos contra pac1 e usos dos mesmos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS277405B6 (en) * 1986-06-12 1993-03-17 Vyzk Ustav Farm Biochem Sp Peptides with 1-amino-1-cycloalkane carboxylic acid
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5623050A (en) * 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
JP3354173B2 (ja) * 1991-08-22 2002-12-09 武田薬品工業株式会社 ポリペプチドおよびその用途
JPH10505863A (ja) * 1994-09-22 1998-06-09 ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド 脳障害の予防および治療のための方法および医薬組成物
AU5441096A (en) * 1995-04-14 1996-10-30 The Administrators Of The Tulane Eductional Fund Analogs of growth hormone-releasing factor
US5753206A (en) * 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
WO1996041814A1 (fr) * 1995-06-09 1996-12-27 Itoham Foods Inc. Peptide, bronchodilatateur et agent facilitant l'ecoulement sanguin
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
AU6846196A (en) * 1995-08-15 1997-03-12 International Software Machines Programmable compiler

Also Published As

Publication number Publication date
HUP0104934A2 (hu) 2002-04-29
AR019131A1 (es) 2001-12-26
CZ2001253A3 (cs) 2001-11-14
EP2161282A1 (en) 2010-03-10
TWI221845B (en) 2004-10-11
EP1098906B1 (en) 2009-11-25
JP2002521390A (ja) 2002-07-16
AU3826899A (en) 2000-02-14
DK1098906T3 (da) 2010-03-29
ES2335827T3 (es) 2010-04-05
DE69941708D1 (de) 2010-01-07
CA2335341A1 (en) 2000-02-03
EP1098906A1 (en) 2001-05-16
NO20010284L (no) 2001-03-19
PL345583A1 (en) 2001-12-17
ATE449789T1 (de) 2009-12-15
HUP0104934A3 (en) 2002-05-28
WO2000005260A1 (en) 2000-02-03
JP2010189398A (ja) 2010-09-02

Similar Documents

Publication Publication Date Title
NO20010284D0 (no) Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP)
HUP0202175A2 (en) Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
PL377025A1 (pl) Agoniści receptora peptydu aktywującego przysadkową cyklazę adenylową (PACAP) -VPAC2 i ich farmakologiczne sposoby zastosowania
DK1137666T5 (da) GLP-1-analoger
NO20012786L (no) Analoger av GLP-1
HUP9802372A3 (en) Cyclic peptide analogs of somatostatin
DK0966297T3 (da) Regulering af gastroinstestinal motilitet
DZ3388A1 (fr) Analogues de peptide 1 du type glucagon
DK1531791T3 (da) Forebyggelse og begrænsning af iskæmi
ES2169251T3 (es) Peptidos de somatostatina.
DK0946191T3 (da) Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme
ZA984077B (en) Peptide parathyroid hormone analogs
DK0775160T3 (da) Cycliske hexapeptidsomatostatin-analoger
DE69720207T2 (de) Peptide mit spezifischer affinität für pacap typ 1 rezeptoren
BR9711002A (pt) Análogos ao hormÈnio da paratireóide para o tratamento da osteoporose
TR199501630A2 (tr) Peptid p277 benzerleri ve diagnoz ve dibetlerin'lerin tedavisi icin onlari iceren kompozisyonlar.
Luis et al. Characterization of VIP-and helodermin-preferring receptors on human small cell lung carcinoma cell lines
CA2407514A1 (en) Rgd (arg-gly-asp) coupled to (neuro)peptides
NO20000575D0 (no) Rekombinant ekspresjon av insulin C-peptid
GB9103344D0 (en) Therapeutic use of somatostatin peptides
UA27997C2 (uk) Агент екстракції периплазматичного рекомбінантного білка, спосіб одержання периплазматичного рекомбінантного білка (варіанти), спосіб культивування прокаріотичного мікроорганізму
DE3467581D1 (en) Gastric secretion inhibiting peptide derivatives, process for their preparation and medicines containing them
ATE226083T1 (de) Verkapselung wasserlöslicher peptide
ITMI951670A0 (it) Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
EE200000694A (et) Inimese rekombinantse iterferooni beeta-1a (IFN-ß-1a) formulatsioon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application